Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / COM NEW
-
Number of holders
-
58
-
Total 13F shares, excl. options
-
6.01M
-
Shares change
-
+441K
-
Total reported value, excl. options
-
$36.1M
-
Value change
-
+$2.41M
-
Put/Call ratio
-
1.51
-
Number of buys
-
32
-
Number of sells
-
-31
-
Price
-
$6.01
Significant Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q3 2018
86 filings reported holding GALT - GALECTIN THERAPEUTICS INC - COM NEW as of Q3 2018.
GALECTIN THERAPEUTICS INC - COM NEW (GALT) has 58 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.01M shares
.
Largest 10 shareholders include Vanguard Group Inc (1.43M shares), D.A. DAVIDSON & CO. (689K shares), BlackRock Inc. (602K shares), Advisor Group, Inc. (598K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (452K shares), Invesco Ltd. (259K shares), FIRST FOUNDATION ADVISORS (246K shares), Benchmark Capital Advisors (223K shares), GEODE CAPITAL MANAGEMENT, LLC (212K shares), and BANK OF MONTREAL /CAN/ (167K shares).
This table shows the top 58 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.